绝经前子宫内膜上皮内瘤变患者全身孕激素与孕激素释放宫内节育器治疗
利用MarketScan数据库分析2008至2020年18-50岁子宫内膜上皮内瘤变患者,比较子宫切除与孕激素治疗趋势。孕激素使用从2008年44.2%升至2020年63.4%(P=.002),其中孕激素释放宫内节育器使用从7.7%升至35.6%(P<.001)。孕激素释放宫内节育器者最终子宫切除率36.0% vs 22.9%(P<.001),后续子宫癌发生率10.5% vs 8.2%(P=.24),静脉血栓栓塞率相似。
要点
- 孕激素保守治疗比例从2008年44.2%升至2020年63.4%。
- 孕激素使用者中宫内节育器使用从2008年7.7%升至2020年35.6%。
- 孕激素释放宫内节育器者子宫切除率22.9%低于全身孕激素者36.0%。
核心结论
- 绝经前子宫内膜上皮内瘤变患者采用孕激素保守治疗的比例随时间增加,孕激素使用者中孕激素释放宫内节育器使用增加。
- 与口服孕激素相比,孕激素释放宫内节育器使用可能与较低的子宫切除率相关,静脉血栓栓塞率相似。
研究设计与样本
- 使用MarketScan数据库识别2008至2020年18-50岁子宫内膜上皮内瘤变患者,共3947例。
- 主要治疗分为子宫切除或孕激素治疗,孕激素组再分为全身治疗或孕激素释放宫内节育器。
- 采用多变量逻辑回归模型分析基线特征与孕激素使用的关联。
- 分析孕激素治疗开始后子宫切除、子宫癌和妊娠的累积发生率。
主要发现
- 3947例中子宫切除2149例(54.4%),孕激素治疗1798例(45.6%)。
- 孕激素使用从2008年44.2%增至2020年63.4%(P=.002)。
- 孕激素使用者中全身孕激素1530例(85.1%),孕激素释放宫内节育器268例(14.9%)。
- 孕激素使用者中宫内节育器使用从2008年7.7%增至2020年35.6%(P<.001)。
- 全身孕激素者最终子宫切除率36.0%(95%CI 32.8-39.3%),孕激素释放宫内节育器者22.9%(95%CI 16.5-30.0%)(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate trends in use and outcomes of progestin therapy for premenopausal patients with endometrial intraepithelial neoplasia. METHODS: The MarketScan Database was used to identify patients aged 18-50 years with endometrial intraepithelial neoplasia from 2008 to 2020. Primary treatment was classified as hysterectomy or progestin-based therapy. Within the progestin group, treatment was classified as systemic therapy or progestin-releasing intrauterine device (IUD). The trends in use of progestins and the pattern of progestin use were examined. A multivariable logistic regression model was fit to examine the association between baseline characteristics and the use of progestins. The cumulative incidence of hysterectomy, uterine cancer, and pregnancy since initiation of progestin therapy was analyzed. RESULTS: A total of 3,947 patients were identified. Hysterectomy was performed in 2,149 (54.4%); progestins were used in 1,798 (45.6%). Use of progestins increased from 44.2% in 2008 to 63.4% in 2020 ( P =.002). Among the progestin users, 1,530 (85.1%) were treated with systemic progestin, and 268 (14.9%) were treated with progestin-releasing IUD. Among progestin users, use of IUD increased from 7.7% in 2008 to 35.6% in 2020 ( P <.001). Hysterectomy was ultimately performed in 36.0% (95% CI 32.8-39.3%) of those who received systemic progestins compared with 22.9% (95% CI 16.5-30.0%) of those treated with progestin-releasing IUD ( P <.001). Subsequent uterine cancer was documented in 10.5% (95% CI 7.6-13.8%) of those who received systemic progestins compared with 8.2% (95% CI 3.1-16.6%) of those treated with progestin-releasing IUD ( P =.24). Venous thromboembolic complications occurred in 27 (1.5%) of those treated with progestins; the venous thromboembolism (VTE) rate was similar for oral progestins and progestin-releasing IUD. CONCLUSION: The rate of conservative treatment with progestins in premenopausal individuals with endometrial intraepithelial neoplasia has increased over time, and among progestin users, progestin-releasing IUD use is increasing. Progestin-releasing IUD use may be associated with a lower rate of hysterectomy and a similar rate of VTE compared with oral progestin therapy.
引用
- Suzuki Y, Chen L, Hou JY, et al. Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2023. PMID: 37023446. doi:10.1097/AOG.0000000000005124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。